ProText Mobility, Inc. (TXTM)
USD 0.0
(-9.09%)
USD 0.0
(-9.09%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -52.64 Thousand USD | 12.46% |
| 2022 | 539.22 Thousand USD | 30.08% |
| 2021 | -86 Thousand USD | -4.88% |
| 2020 | -82 Thousand USD | -147.71% |
| 2019 | -1.42 Million USD | 153.46% |
| 2018 | -431.99 Thousand USD | 35.64% |
| 2017 | -499.57 Thousand USD | -72.03% |
| 2016 | -290.4 Thousand USD | 0.0% |
| 2013 | -927.3 Thousand USD | 33.86% |
| 2012 | -1.4 Million USD | 30.49% |
| 2011 | -2.72 Million USD | 39.73% |
| 2010 | -4.3 Million USD | 7.17% |
| 2009 | -3.76 Million USD | -9.25% |
| 2008 | -3.29 Million USD | -208.9% |
| 2007 | -2.35 Million USD | 56.82% |
| 2006 | -2.47 Million USD | -62.34% |
| 2005 | -3.22 Million USD | -85.93% |
| 2004 | -970.94 Thousand USD | -34.63% |
| 2003 | -777.93 Thousand USD | -159.1% |
| 2002 | -297.4 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -4530.00 USD | 76.66% |
| 2024 Q1 | -19.41 Thousand USD | -266.23% |
| 2023 Q3 | -6420.00 USD | 75.02% |
| 2023 Q4 | -5300.00 USD | 17.45% |
| 2023 FY | - USD | 12.46% |
| 2023 Q1 | -15.22 Thousand USD | -121.22% |
| 2023 Q2 | -25.7 Thousand USD | -68.86% |
| 2022 Q2 | -25 Thousand USD | -13.64% |
| 2022 FY | - USD | 30.08% |
| 2022 Q1 | -22 Thousand USD | 0.0% |
| 2022 Q3 | -6740.00 USD | 73.04% |
| 2022 Q4 | -6880.00 USD | -2.08% |
| 2021 Q3 | -24 Thousand USD | -20.0% |
| 2021 Q1 | -20 Thousand USD | 0.0% |
| 2021 FY | - USD | -4.88% |
| 2021 Q2 | -20 Thousand USD | 0.0% |
| 2021 Q4 | -22 Thousand USD | 8.33% |
| 2020 FY | - USD | -147.71% |
| 2019 FY | - USD | 153.46% |
| 2018 FY | - USD | 35.64% |
| 2017 FY | - USD | -72.03% |
| 2016 FY | - USD | 0.0% |
| 2014 Q1 | -220.39 Thousand USD | 26.41% |
| 2014 Q3 | -261.15 Thousand USD | -5.04% |
| 2014 Q2 | -248.62 Thousand USD | -12.81% |
| 2013 Q1 | -194.73 Thousand USD | 71.37% |
| 2013 FY | - USD | 33.86% |
| 2013 Q4 | -299.48 Thousand USD | -23.65% |
| 2013 Q2 | -190.88 Thousand USD | 1.98% |
| 2013 Q3 | -242.19 Thousand USD | -26.88% |
| 2012 Q1 | -294.17 Thousand USD | 59.92% |
| 2012 Q3 | -217.01 Thousand USD | -15.38% |
| 2012 FY | - USD | 30.49% |
| 2012 Q4 | -680.29 Thousand USD | -213.48% |
| 2012 Q2 | -188.09 Thousand USD | 36.06% |
| 2011 Q1 | -780.41 Thousand USD | 30.73% |
| 2011 Q2 | -507.62 Thousand USD | 34.95% |
| 2011 Q3 | -530.74 Thousand USD | -4.55% |
| 2011 Q4 | -733.9 Thousand USD | -38.28% |
| 2011 FY | - USD | 39.73% |
| 2010 Q2 | -852.11 Thousand USD | -8.34% |
| 2010 FY | - USD | 7.17% |
| 2010 Q4 | -1.12 Million USD | -93.73% |
| 2010 Q3 | -581.56 Thousand USD | 31.75% |
| 2010 Q1 | -786.53 Thousand USD | -176.31% |
| 2009 Q4 | -284.66 Thousand USD | 77.32% |
| 2009 FY | - USD | -9.25% |
| 2009 Q1 | -887.88 Thousand USD | 67.49% |
| 2009 Q2 | -615.5 Thousand USD | 30.68% |
| 2009 Q3 | -1.25 Million USD | -103.91% |
| 2008 FY | - USD | -208.9% |
| 2008 Q4 | -2.73 Million USD | -22.73% |
| 2008 Q3 | -2.22 Million USD | -122.44% |
| 2008 Q2 | -1 Million USD | -70.67% |
| 2008 Q1 | -586.1 Thousand USD | -179.1% |
| 2007 Q4 | 740.99 Thousand USD | 247.04% |
| 2007 FY | - USD | 56.82% |
| 2007 Q2 | -895.9 Thousand USD | -118.81% |
| 2007 Q1 | -409.45 Thousand USD | 33.66% |
| 2007 Q3 | -503.94 Thousand USD | 43.75% |
| 2006 Q3 | -441.58 Thousand USD | 46.6% |
| 2006 FY | - USD | -62.34% |
| 2006 Q2 | -826.97 Thousand USD | -379.97% |
| 2006 Q1 | -172.29 Thousand USD | 63.85% |
| 2006 Q4 | -617.19 Thousand USD | -39.77% |
| 2005 Q2 | -297.34 Thousand USD | -403.94% |
| 2005 FY | - USD | -85.93% |
| 2005 Q1 | -59 Thousand USD | 31.58% |
| 2005 Q3 | -507.15 Thousand USD | -70.56% |
| 2005 Q4 | -476.63 Thousand USD | 6.02% |
| 2004 FY | - USD | -34.63% |
| 2004 Q2 | -213.33 Thousand USD | 27.87% |
| 2004 Q3 | -224.42 Thousand USD | -5.2% |
| 2004 Q1 | -295.74 Thousand USD | 35.89% |
| 2004 Q4 | -86.24 Thousand USD | 61.57% |
| 2003 Q1 | -115.49 Thousand USD | 0.0% |
| 2003 FY | - USD | -159.1% |
| 2003 Q4 | -461.28 Thousand USD | -518.66% |
| 2003 Q3 | -81.91 Thousand USD | -64.81% |
| 2003 Q2 | -118.74 Thousand USD | -65.74% |
| 2002 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 99.926% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 99.112% |
| SQZ Biotechnologies Company | -64.14 Million USD | 99.918% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 99.697% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 100.056% |
| Mesoblast Limited | -62.38 Million USD | 99.916% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 96.573% |
| Genus plc | 73.7 Million USD | 100.071% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 99.204% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 98.516% |
| Marizyme, Inc. | -34.28 Million USD | 99.846% |
| ContraFect Corporation | -64.99 Million USD | 99.919% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 99.4% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 98.837% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 96.245% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 98.009% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 97.735% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 89.839% |
| Accustem Sciences Inc. | -3.74 Million USD | 98.595% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 99.891% |
| EV Biologics, Inc. | -1.26 Million USD | 95.846% |
| Q BioMed Inc. | -617.62 Thousand USD | 91.477% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 101.474% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 91.676% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 97.696% |
| Biomind Labs Inc. | -1.03 Million USD | 94.912% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 100.533% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 99.265% |
| Skye Bioscience, Inc. | -13.54 Million USD | 99.611% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 96.461% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -110.56% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 98.645% |
| IMV Inc. | -35.52 Million USD | 99.852% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 99.668% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 97.896% |
| GB Sciences, Inc. | -1.41 Million USD | 96.293% |
| Alpha Cognition Inc. | -9.7 Million USD | 99.458% |
| HST Global, Inc. | -5303.00 USD | -892.646% |
| CSL Limited | 4.78 Billion USD | 100.001% |
| Halberd Corporation | -74.27 Thousand USD | 29.132% |
| Enzolytics Inc. | -2.12 Million USD | 97.519% |
| Resverlogix Corp. | -11.74 Million USD | 99.552% |
| Affymax, Inc. | -14.29 Million USD | 99.632% |
| SYBLEU INC | -141.57 Thousand USD | 62.817% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 98.281% |
| argenx SE | -216.02 Million USD | 99.976% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 99.905% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 104.325% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 96.488% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 113.895% |
| AVAX Technologies, Inc. | -6.11 Million USD | 99.139% |
| Zenith Capital Corp. | -8.6 Million USD | 99.388% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.979% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -202.164% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 97.848% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 70.095% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 99.867% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 98.18% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | 94.969% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 882.867% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 96.992% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 97.26% |
| BioStem Technologies, Inc. | -7.55 Million USD | 99.303% |
| ONE Bio Corp. | 13.61 Million USD | 100.387% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 70.931% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 97.441% |
| Agentix Corp. | -1.37 Million USD | 96.163% |
| LadRx Corporation | 412.28 Thousand USD | 112.768% |
| Cell Source, Inc. | -4.27 Million USD | 98.768% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 85.665% |
| Regen BioPharma, Inc. | 1.46 Million USD | 103.591% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 94.382% |
| NovAccess Global Inc. | -1.03 Million USD | 94.913% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 100.595% |
| Itoco Inc. | -1.86 Million USD | 97.184% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 86.134% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 95.283% |
| Kadimastem Ltd | -2.62 Million USD | 97.994% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 77.989% |
| CytoDyn Inc. | -18.02 Million USD | 99.708% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 33.392% |
| Mobile Lads Corp. | -2.24 Million USD | 97.651% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -330.452% |
| Qrons Inc. | -40.08 Thousand USD | -31.334% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 89.162% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 109.98% |
| Rebus Holdings, Inc. | -951 Thousand USD | 94.465% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 95.043% |
| International Stem Cell Corporation | 202 Thousand USD | 126.059% |
| Bioxytran, Inc. | -3.82 Million USD | 98.622% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 97.862% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 99.853% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -16.978% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 98.077% |
| Neutra Corp. | -181.24 Thousand USD | 70.957% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 99.739% |
| PureTech Health plc | -11.62 Million USD | 99.547% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 99.739% |
| IXICO plc | -707 Thousand USD | 92.554% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 99.315% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 99.891% |
| CSL Limited | 4.73 Billion USD | 100.001% |
| Cellectis S.A. | -92.63 Million USD | 99.943% |